SABBY MANAGEMENT, LLC - Q3 2013 holdings

Add to watchlist

$1.54 Billion is the total value of SABBY MANAGEMENT, LLC's 194 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 188.2% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
BuyVERTEX PHARMACEUTICALS INCcall$188,716,000
+2.4%
24,890
+7.9%
12.26%
-0.3%
BuyMERCK & CO INCcall$82,165,000
+33.6%
17,258
+30.3%
5.34%
+30.1%
BuyACADIA PHARMACEUTICALS INCcall$81,976,000
+79.4%
29,842
+18.5%
5.33%
+74.6%
BuySAREPTA THERAPEUTICS INCput$61,531,000
+195.6%
13,028
+138.1%
4.00%
+187.9%
NewISHARES MSCI JAPAN ETFput$59,550,000–50,000
+100.0%
3.87%–
BuyGILEAD SCIENCES INCput$53,452,000
+38.6%
8,506
+13.0%
3.47%
+35.0%
BuyVERTEX PHARMACEUTICALS INCput$49,670,000
+18.3%
6,551
+24.6%
3.23%
+15.2%
NewISHARES 20+ YEAR TREASURY BOND ETFcall$45,220,000–4,250
+100.0%
2.94%–
NewISHARES RUSSELL 2000 ETFput$37,082,000–3,478
+100.0%
2.41%–
NewGLAXOSMITHKLINE PLCcall$32,766,000–6,531
+100.0%
2.13%–
BuyMEDIVATION INCput$29,478,000
+374.0%
4,918
+289.1%
1.92%
+361.7%
BuyBRISTOL MYERS SQUIBB COcall$28,411,000
+275.1%
6,139
+262.2%
1.85%
+264.8%
BuyAEGERION PHARMACEUTICALS INCput$26,390,000
+75.8%
3,079
+29.9%
1.72%
+71.2%
VRTX BuyVERTEX PHARMACEUTICALS INC$25,548,000
+2016.7%
336,955
+2130.3%
1.66%
+1949.4%
SRPT BuySAREPTA THERAPEUTICS INC$24,656,000
+42.4%
522,041
+14.8%
1.60%
+38.7%
BuyISHARES 20+ YEAR TREASURY BOND ETFput$23,940,000
+8.4%
2,250
+12.5%
1.56%
+5.6%
NewBIOGEN IDEC INCcall$21,042,000–874
+100.0%
1.37%–
BuyAEGERION PHARMACEUTICALS INCcall$18,856,000
+162.3%
2,200
+93.8%
1.22%
+155.2%
BuyALLERGAN INCput$18,388,000
+332.3%
2,033
+302.6%
1.20%
+320.8%
BuyCELGENE CORPput$18,133,000
+170.2%
1,178
+105.2%
1.18%
+162.9%
NewOPKO HEALTH INCcall$16,767,000–19,032
+100.0%
1.09%–
NewCELLDEX THERAPEUTICS INCcall$16,234,000–4,582
+100.0%
1.06%–
BuyREPROS THERAPEUTICS INCput$15,362,000
+255.2%
5,732
+144.5%
1.00%
+245.3%
BuyCUBIST PHARMACEUTICALS INCcall$13,968,000
+126.5%
2,198
+72.1%
0.91%
+120.4%
BuyWELLCARE HEALTH PLANS INCcall$12,979,000
+29.4%
1,861
+3.1%
0.84%
+26.2%
ALXN NewALEXION PHARMACEUTICALS INCcall$12,963,000–1,116
+100.0%
0.84%–
BuySAREPTA THERAPEUTICS INCcall$12,795,000
+48.9%
2,709
+19.9%
0.83%
+44.9%
BuyARENA PHARMACEUTICALS INCcall$10,835,000
+37.8%
20,560
+101.3%
0.70%
+34.1%
NewASTRAZENECA PLC-SPONS ADRput$10,698,000–2,060
+100.0%
0.70%–
BuyMANNKIND CORPput$9,043,000
+55.3%
15,865
+77.1%
0.59%
+51.2%
BuyNEWLINK GENETICS CORPcall$9,033,000
+15.4%
4,810
+21.2%
0.59%
+12.5%
BuyAMARIN CORPORATION PLC -ADRcall$7,302,000
+47.9%
11,554
+35.7%
0.48%
+43.9%
BuyACHILLION PHARMACEUTICALS INCcall$7,290,000
+19.1%
24,139
+222.7%
0.47%
+16.2%
ANTH NewANTHERA PHARMACEUTICALS INC$7,053,000–1,754,600
+100.0%
0.46%–
BuyMEDIVATION INCcall$6,863,000
+84.7%
1,145
+51.7%
0.45%
+79.8%
MDVN BuyMEDIVATION INC$6,764,000
+187.0%
112,849
+135.6%
0.44%
+180.3%
BuyINTERMUNE INCcall$6,400,000
+105.1%
4,164
+28.4%
0.42%
+100.0%
NewPHARMACYCLICS INCcall$6,229,000–450
+100.0%
0.40%–
BuyOPKO HEALTH INCput$6,027,000
+100.2%
6,841
+61.3%
0.39%
+95.0%
NewGLAXOSMITHKLINE PLCput$5,920,000–1,180
+100.0%
0.38%–
NewSYNAGEVA BIOPHARMA CORPcall$5,825,000–920
+100.0%
0.38%–
MNKD BuyMANNKIND CORP$5,324,000
+539.9%
934,021
+629.7%
0.35%
+517.9%
NewBLACKBERRY LTDput$5,005,000–6,296
+100.0%
0.32%–
AGEN NewAGENUS INC$4,885,000–1,763,663
+100.0%
0.32%–
BuyPBF ENERGY INCcall$4,479,000
+456.4%
1,995
+541.5%
0.29%
+438.9%
NewCELLDEX THERAPEUTICS INCput$4,032,000–1,138
+100.0%
0.26%–
RPRX BuyREPROS THERAPEUTICS INC$3,961,000
+245.6%
147,783
+138.0%
0.26%
+238.2%
OGXI BuyONCOGENEX PHARMACEUTICAL INC$3,806,000
-2.1%
410,577
+3.5%
0.25%
-5.0%
NewISIS PHARMACEUTICALS INCput$3,762,000–1,002
+100.0%
0.24%–
NWBO BuyNORTHWEST BIOTHERAPEUTICS$3,278,000
+12.7%
978,359
+12.4%
0.21%
+9.8%
EDAP BuyEDAP TMS SA -ADRadr$3,187,000
-2.5%
1,259,500
+5.2%
0.21%
-5.0%
NewBIOMARIN PHARMACEUTICAL INCcall$3,012,000–417
+100.0%
0.20%–
BuyARIAD PHARMACEUTICALS INCput$2,997,000
+258.5%
1,629
+240.8%
0.20%
+248.2%
NVAX NewNOVAVAX INC$2,765,000–875,000
+100.0%
0.18%–
NewEXELIXIS INCcall$2,425,000–4,167
+100.0%
0.16%–
BuyREPROS THERAPEUTICS INCcall$2,318,000
+528.2%
865
+332.5%
0.15%
+504.0%
NewHOLOGIC INCcall$2,292,000–1,110
+100.0%
0.15%–
NewACADIA PHARMACEUTICALS INCput$2,288,000–833
+100.0%
0.15%–
NewINSMED INCput$2,248,000–1,440
+100.0%
0.15%–
NewPHARMACYCLICS INCput$2,146,000–155
+100.0%
0.14%–
SZYM NewSOLAZYME INC$2,136,000–198,350
+100.0%
0.14%–
NewSOLAZYME INCput$2,115,000–1,964
+100.0%
0.14%–
ENMD BuyENTREMED INC$2,063,000
-12.9%
1,178,956
+0.5%
0.13%
-15.2%
XOMA NewXOMA CORP$2,041,000–455,672
+100.0%
0.13%–
NewMEDICINES COcall$2,028,000–605
+100.0%
0.13%–
NewVANDA PHARMACEUTICALS INCcall$2,004,000–1,827
+100.0%
0.13%–
BuySYNTA PHARMACEUTICALS CORPput$1,887,000
+73.6%
2,991
+37.3%
0.12%
+68.5%
BuyGALENA BIOPHARMA INCput$1,814,000
+532.1%
7,990
+518.9%
0.12%
+521.1%
BuyUNI-PIXEL INCput$1,769,000
+103.1%
998
+68.6%
0.12%
+98.3%
PCYC NewPHARMACYCLICS INC$1,709,000–12,350
+100.0%
0.11%–
LLY BuyELI LILLY & CO$1,669,000
+86.5%
33,156
+82.0%
0.11%
+80.0%
NewVANDA PHARMACEUTICALS INCput$1,662,000–1,515
+100.0%
0.11%–
BuyARIAD PHARMACEUTICALS INCcall$1,601,000
+211.5%
870
+195.9%
0.10%
+205.9%
OVAS NewOVASCIENCE INC$1,605,000–162,000
+100.0%
0.10%–
ACRX NewACELRX PHARMACEUTICALS INC$1,595,000–148,070
+100.0%
0.10%–
SNTA BuySYNTA PHARMACEUTICALS CORP$1,584,000
+46.8%
250,952
+16.0%
0.10%
+43.1%
ACHN NewACHILLION PHARMACEUTICALS INC$1,464,000–484,879
+100.0%
0.10%–
ASTM NewAASTROM BIOSCIENCES INC$1,437,000–5,189,214
+100.0%
0.09%–
TGTX NewTG THERAPEUTICS INC$1,402,000–275,479
+100.0%
0.09%–
AZN NewASTRAZENECA PLC-SPONS ADRadr$1,381,000–26,585
+100.0%
0.09%–
ONTY NewONCOTHYREON INC$1,359,000–659,600
+100.0%
0.09%–
NewUNITED THERAPEUTICS CORPcall$1,325,000–168
+100.0%
0.09%–
NewEXACT SCIENCES CORPcall$1,211,000–1,025
+100.0%
0.08%–
NewUNI-PIXEL INCcall$1,200,000–677
+100.0%
0.08%–
CLDX NewCELLDEX THERAPEUTICS INC$1,133,000–31,979
+100.0%
0.07%–
FCSC NewFIBROCELL SCIENCE INC$1,099,000–251,000
+100.0%
0.07%–
NewAVANIR PHARMACEUTICALS INCput$1,074,000–2,534
+100.0%
0.07%–
TEVA BuyTEVA PHARMACEUTICAL INDUSTRIES LTD$1,081,000
+33.0%
28,603
+37.9%
0.07%
+29.6%
ISR NewISORAY INC$1,079,000–1,663,098
+100.0%
0.07%–
NewACCURAY INCput$1,035,000–1,400
+100.0%
0.07%–
TMP NewTONIX PHARMACEUTICALS HOLDING$1,024,000–288,454
+100.0%
0.07%–
RNN NewREXAHN PHARMACEUTICALS INC$1,013,000–2,250,840
+100.0%
0.07%–
SCON NewSUPERCONDUCTOR TECHNOLOGIES$1,004,000–619,600
+100.0%
0.06%–
NewNEKTAR THERAPEUTICSput$941,000–900
+100.0%
0.06%–
CNAT NewCONATUS PHARMACEUTICALS INC$921,000–91,600
+100.0%
0.06%–
NewIMMUNOCELLULAR THERAPEUTICS LTDput$914,000–3,557
+100.0%
0.06%–
ASTX NewASTEX PHARMACEUTICALS INC$845,000–99,703
+100.0%
0.06%–
BuyACHILLION PHARMACEUTICALS INCput$802,000
-54.8%
2,654
+22.5%
0.05%
-55.9%
NewSYNTA PHARMACEUTICALS CORPcall$791,000–1,253
+100.0%
0.05%–
BuyCORONADO BIOSCIENCES INCcall$748,000
+78.1%
1,066
+118.4%
0.05%
+75.0%
ARAY BuyACCURAY INC$739,000
+202.9%
100,000
+135.3%
0.05%
+200.0%
NewXOMA CORPput$742,000–1,656
+100.0%
0.05%–
VICL NewVICAL INC$727,000–581,595
+100.0%
0.05%–
RIGL NewRIGEL PHARMACEUTICALS INC$710,000–198,259
+100.0%
0.05%–
BuyCELSION CORPORATIONput$710,000
+202.1%
6,174
+168.2%
0.05%
+187.5%
NewZIOPHARM ONCOLOGY INCput$712,000–1,803
+100.0%
0.05%–
NSPH NewNANOSPHERE INC$690,000–345,121
+100.0%
0.04%–
NewNEKTAR THERAPEUTICScall$686,000–656
+100.0%
0.04%–
NewGERON CORPput$697,000–2,080
+100.0%
0.04%–
DYAX NewDYAX CORP$682,000–99,458
+100.0%
0.04%–
ARIA NewARIAD PHARMACEUTICALS INC$581,000–31,553
+100.0%
0.04%–
BuyTRANSCEPT PHARMACEUTICALS INCput$551,000
+5.4%
1,733
+0.1%
0.04%
+2.9%
NewENDOCYTE INCput$547,000–410
+100.0%
0.04%–
ONXX NewONYX PHARMACEUTICALS INC$504,000–4,045
+100.0%
0.03%–
SLXP NewSALIX PHARMACEUTICALS LTD$473,000–7,073
+100.0%
0.03%–
KBIO NewKALOBIOS PHARMACEUTICALS INC$476,000–105,408
+100.0%
0.03%–
NewMEI PHARMAcall$454,000–400
+100.0%
0.03%–
NewBIOCRYST PHARMACEUTICALS INCcall$446,000–613
+100.0%
0.03%–
ISIS NewISIS PHARMACEUTICALS INC$438,000–11,663
+100.0%
0.03%–
NewCUBIST PHARMACEUTICALS INCput$394,000–62
+100.0%
0.03%–
GERN NewGERON CORP$366,000–109,375
+100.0%
0.02%–
NewNUPATHE INCput$369,000–1,531
+100.0%
0.02%–
ACOR NewACORDA THERAPEUTICS INCcall$369,000–108
+100.0%
0.02%–
NewGERON CORPcall$376,000–1,122
+100.0%
0.02%–
NewPLURISTEM THERAPEUTICS INCput$351,000–1,038
+100.0%
0.02%–
NBIX NewNEUROMETRIX INC$361,000–218,849
+100.0%
0.02%–
BuyOREXIGEN THERAPEUTICS INCput$345,000
+35.3%
562
+28.9%
0.02%
+29.4%
BuyCORONADO BIOSCIENCES INCput$304,000
+7.4%
433
+31.6%
0.02%
+5.3%
EWJ NewISHARES MSCI JAPAN ETFetf$298,000–25,000
+100.0%
0.02%–
NewBRISTOL MYERS SQUIBB COput$278,000–60
+100.0%
0.02%–
DNDNQ NewDENDREON CORP$263,000–89,800
+100.0%
0.02%–
NewARROWHEAD RESEARCH CORPcall$250,000–439
+100.0%
0.02%–
NewONCOTHYREON INCcall$230,000–1,116
+100.0%
0.02%–
NewACELRX PHARMACEUTICALS INCcall$215,000–200
+100.0%
0.01%–
NewACCURAY INCcall$188,000–254
+100.0%
0.01%–
NewENDOCYTE INCcall$143,000–107
+100.0%
0.01%–
NewAPRICUS BIOSCIENCES INCput$109,000–264
+100.0%
0.01%–
NewCHEMOCENTRYX INCput$86,000–155
+100.0%
0.01%–
NewAGENUS INCcall$96,000–347
+100.0%
0.01%–
NewSEQUENOM INCcall$78,000–293
+100.0%
0.01%–
OXBT NewOXYGEN BIOTHERAPEUTICS INC$54,000–36,715
+100.0%
0.00%–
NewSEQUENOM INCput$55,000–205
+100.0%
0.00%–
NewATHERSYS INCput$40,000–245
+100.0%
0.00%–
NewCYTRX CORPcall$40,000–125
+100.0%
0.00%–
SQNM NewSEQUENOM INC$41,000–15,400
+100.0%
0.00%–
NewONCOLYTICS BIOTECH INCcall$24,000–100
+100.0%
0.00%–
NewATHERSYS INCcall$22,000–133
+100.0%
0.00%–
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2013-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SPDR S&P 500 ETF TRUST UNIT37Q3 202349.1%
ISHARES TR35Q3 202352.2%
SPDR S&P BIOTECHNOLOGY32Q3 202212.8%
AMARIN CORP PLC30Q4 20212.0%
BIOGEN INC24Q1 202126.2%
SAREPTA THERAPEUTICS INC24Q3 20204.6%
BIOGEN INC23Q1 202113.7%
SAREPTA THERAPEUTICS INC22Q3 20206.2%
BRAINSTORM CELL THERAPEUTICS INC21Q3 20231.6%
VERTEX PHARMACEUTICALS INC20Q1 201812.6%

View SABBY MANAGEMENT, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
SABBY MANAGEMENT, LLC Q3 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AGM GROUP HOLDINGS, INC.January 10, 2023627,9362.6%
Bit Digital, IncJanuary 10, 20233,166,9173.8%
Cingulate Inc.January 10, 2023105.0%
Context Therapeutics Inc.January 10, 2023796,7065.0%
HeartBeam, Inc.January 10, 2023271,7883.4%
PharmaCyte Biotech, Inc.January 10, 2023934,4565.0%
Rebus Holdings, Inc.Sold outJanuary 10, 202300.0%
TANTECH HOLDINGS LTDJanuary 10, 202341,5000.6%
Quanergy Systems, Inc.January 04, 2023936,9055.8%
TuanChe LtdJanuary 04, 20232,384,71310.0%

View SABBY MANAGEMENT, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-04
SC 13G2024-01-03
SC 13G2024-01-03
SC 13G2024-01-03

View SABBY MANAGEMENT, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export SABBY MANAGEMENT, LLC's holdings

CSVXLS